Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirosint-SOL vs Levothyroxine Tablets in Neonates and Infants With Congenital Hypothyroidism
NCT05228184Phase 4Terminated
- Sponsor
- IBSA Group
- Start
- Jan 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of levothyroxine sodium in congenital hypothyroidism (CH) (2 arms), sponsored by IBSA Group. Primary endpoint: LT4 Dose Required to Maintain TSH in Target Range at 1 year. Started Jan 2022; status: terminated.
02
Drugs
levothyroxine sodium
03
Conditions
congenital hypothyroidism (CH)
Beyond the preview
Go deeper on NCT05228184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05228184.